Lead Product(s) : Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Biotest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Biotest
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Cytomegalovirus Immune Globulin,Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Kamada
Deal Size : $145.0 million
Deal Type : Acquisition
Details : Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.
Product Name : Cytogam
Product Type : Protein
Upfront Cash : $95.0 million
November 22, 2021
Lead Product(s) : Human Cytomegalovirus Immune Globulin,Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Kamada
Deal Size : $145.0 million
Deal Type : Acquisition
Lead Product(s) : Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2015
Lead Product(s) : Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ganciclovir
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2012
Lead Product(s) : Ganciclovir
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ganciclovir
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2012
Lead Product(s) : Ganciclovir
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ganciclovir
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : National Heart, Lung, and Blood Institute | Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2011
Lead Product(s) : Ganciclovir
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : National Heart, Lung, and Blood Institute | Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ganciclovir
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 19, 2010
Lead Product(s) : Ganciclovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
